Skip to main content
Premium Trial:

Request an Annual Quote

French Commission of Atomic Energy, Sir Mortimer B. Davis-Jewish General Hospital, Harvard University

Premium

The French Commission of Atomic Energy received US Patent No. 6,510,237, “System for determining the concentration of a substance mixed with a fluorophor, its method of implementation.” The patent covers a reader used in analysis of the Micam-brand DNA chips produced by the commission’s Laboratory of Electronics, Technology and Instrumentation (LETI). The technology determines the concentration of a substance mixed with a fluorophor and contained in an electrically addressable matrix on a reflective carrier. It comprises: a microscope to view the image of the fluorescence of one of the contacts of the matrix, illuminating with a first beam to enable image acquisition in white light, and a second beam to excite the fluorophor contained in the contact; a way to view the contact image; and means to process the image. The equipment used includes a pulsated micro laser, a cooled CCD camera, and a high-pass filter.

The Sir Mortimer B. Davis-Jewish General Hospital of Montreal received US Patent 6,511,849, “Microarrays of biological materials.” The patent covers “relatively simple and inexpensive machinery” to automate the manufacture of microarrays in a reproducible and rapid manner. The process uses ink-jet technology to deposit minute quantities of liquid on a solid substrate. The equipment can be constructed from commercially available components. Part of the technology is a system for cleaning parts of the system to avoid contamination.

Harvard University earned US Patent No. 6,511,803, “Replica amplification of nucleic acid arrays.” The patent covers a method for producing replicas of microarrays and for preserving the resolution through rounds of replication. The patent abstract says the chips can be produced for about $10 a chip and can be reused. The process is described thusly: 1) providing a pool of nucleic acid molecules, 2) plating or other transfer of the pool onto a solid support, 3) in situ amplification, 4) replica printing of the amplified nucleic acids, and 5) identification of features.

 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.